Literature DB >> 20100229

Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients.

M A Sahraian1, Z Moinfar, S Khorramnia, M Mohammad Ebrahim.   

Abstract

BACKGROUND: Neuromyelitis Optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system with distinguishing features from multiple sclerosis (MS). NMO has an unknown etiology with poor prognosis in which anti-aquaporin-4 receptor IgG seems to play a major role. The purpose of this study is to represent a clinical and demographic data of NMO in Iranian population.
METHODS: Of 1800 patients attending our MS clinic, 44 patients with NMO were recruited from 2006 to 2009.
RESULTS: Female to male ratio was 3:1 and the disease affected women in younger ages than men (P = 0.04). The median expanded disability status scale score was 3 and the mean duration of symptoms was 4.53 +/- 3.41 (median = 4) years with annual relapse rate of 1.13 year/patient. The most frequent symptoms at presentation were optic neuritis 22 (50%) and transverse myelitis 14 (31.8%). Out of 12 patients whose titer of NMO-IgG was measured, four (30.7%) patients were seropositive. Twenty-eight patients (63%) received azathioprine for a mean duration of 16.84 +/- 27.91 months with significantly lower annual relapse rate (0.4 year/patient).
CONCLUSIONS: Iranian patients as a Caucasian population living in Asia seem to have the same clinical features in comparison with the reported studies from Western countries. Although the duration of follow-up was not too long, but they may possibly have a more benign course.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100229     DOI: 10.1111/j.1468-1331.2009.02928.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

Review 1.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

2.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

3.  Letter to the Editor: Lack of Attention to Epidemiological Study of Neuromyelitis Optica Spectrum Disorder Compared with that of Multiple Sclerosis in Iran.

Authors:  Abdorreza Naser Moghadasi
Journal:  Int J MS Care       Date:  2019 Nov-Dec

4.  Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.

Authors:  Zahra Nikoo; Shervin Badihian; Vahid Shaygannejad; Nasrin Asgari; Fereshteh Ashtari
Journal:  J Neurol       Date:  2017-08-22       Impact factor: 4.849

5.  Recurrent isolated optic neuritis: A study on 22 patients.

Authors:  Mahsa Arzani; Mohammad Ali Sahraian; Hamed Rezaei; Abdorreza Naser Moghadasi
Journal:  Iran J Neurol       Date:  2017-07-06

Review 6.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

8.  Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.

Authors:  Ming-Feng Liao; Kuo-Hsuan Chang; Rong-Kuo Lyu; Chin-Chang Huang; Hong-Shiu Chang; Yih-Ru Wu; Chiung-Mei Chen; Chun-Che Chu; Hung-Chou Kuo; Long-Sun Ro
Journal:  BMC Neurol       Date:  2014-11-30       Impact factor: 2.474

Review 9.  Therapy of NMO spectrum disorders.

Authors:  Atanu Biswas; Arabinda Mukherjee
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

10.  A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran.

Authors:  Davood Kashipazha; Seyed Ehsan Mohammadianinejad; Nastaran Majdinasab; Mostafa Azizi; Majid Jafari
Journal:  Iran J Neurol       Date:  2015-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.